Wetherby Asset Management Inc. bought a new stake in shares of Mylan (NASDAQ:MYL) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,616 shares of the company’s stock, valued at approximately $238,000.
Several other institutional investors have also made changes to their positions in the company. Itau Unibanco Holding S.A. grew its stake in shares of Mylan by 287.4% during the fourth quarter. Itau Unibanco Holding S.A. now owns 17,840 shares of the company’s stock valued at $755,000 after acquiring an additional 13,235 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of Mylan by 2.7% during the fourth quarter. UBS Asset Management Americas Inc. now owns 1,339,327 shares of the company’s stock worth $56,667,000 after purchasing an additional 35,360 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Mylan by 30.3% during the fourth quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock worth $225,715,000 after purchasing an additional 1,239,089 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Mylan by 3.5% during the fourth quarter. Rhumbline Advisers now owns 818,932 shares of the company’s stock worth $34,649,000 after purchasing an additional 27,469 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Mylan by 4.0% during the fourth quarter. Arizona State Retirement System now owns 201,944 shares of the company’s stock worth $8,544,000 after purchasing an additional 7,742 shares during the last quarter. Institutional investors own 76.86% of the company’s stock.
Mylan (NASDAQ MYL) opened at $41.34 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. Mylan has a twelve month low of $29.39 and a twelve month high of $47.82. The stock has a market cap of $22,605.42, a PE ratio of 25.68, a price-to-earnings-growth ratio of 1.14 and a beta of 1.35.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.69% of the company’s stock.
Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. set a $53.00 price target on shares of Mylan and gave the stock a “buy” rating in a research report on Friday, February 16th. TheStreet cut shares of Mylan from a “b-” rating to a “c+” rating in a research report on Friday, February 9th. BidaskClub cut shares of Mylan from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. Susquehanna Bancshares reaffirmed a “positive” rating and set a $55.00 price target (up previously from $47.00) on shares of Mylan in a research report on Thursday, January 25th. Finally, Deutsche Bank set a $50.00 price target on shares of Mylan and gave the stock a “buy” rating in a research report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $44.89.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/21/wetherby-asset-management-inc-buys-shares-of-5616-mylan-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.